DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/z5srgt/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022" report to their offering.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
The US is the largest hemophilia market, due to the high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. Companies such as Baxter, Bayer, Novo Nordisk, CSL Behring and Biogen Idec will be able to command slight premiums over currently marketed recombinant standard of care therapies, thus contributing to overall market growth.
- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
5.2 Strategic Competitive Assessment
5.3 Product Profiles - Major Brands, Hemophilia A
5.4 Product Profiles - Hemophilia B
5.5 Product Profiles - Hemophilia A and B with Inhibitors
6 Opportunity and Unmet Need
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development - Hemophilia A
7.3 Promising Drugs in Clinical Development - Hemophilia B
7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/z5srgt/pharmapoint